All posts by imreal

InfoBionic Secures Series D Funding to Catalyze Growth of its New MoMe® ARC Virtual Telemetry Solution


InfoBionic, the virtual telemetry company focused on efficiency and economics of cardiac remote patient monitoring, announces initial closing of Series D funding to support continued commercial expansion of its MoMe® ARC system for remote, wireless monitoring and diagnosis of cardiac arrhythmias. The financing round includes participation by Security International Investments (SII), Mayo Clinic and Excel Venture Management.

WALTHAM, Mass., Oct. 16, 2023 /PRNewswire-PRWeb/ — InfoBionic, a digital health company focused on virtual telemetry and cardiac remote patient monitoring, announces the initial closing of its Series D financing round to support continued domestic growth and international expansion of its newly FDA approved MoMe® ARC system for virtual telemetry and remote wireless monitoring and detection of cardiac arrhythmias. “We’re very proud of our role in the evolving transformation of virtual telemetry for remote cardiac monitoring and we are excited at the prospects of what we can accomplish in this next phase of virtual care,” said Stuart Long, CEO of InfoBionic, the leading digital health company that created the MoMe® ARC remote cardiac monitoring platform. The series D funding round includes participation by Security International Investments (SII), Mayo Clinic and Excel Venture Management while distinguished existing investors like Blue Cross Blue Shield of MA (Zaffre Investments), Blue Cross Blue Shield of Kansas and Safeguard Scientifics remain actively involved. “We are pleased by the completion of this latest round which was based on the strong market traction of our proprietary MoMe® Kardia system,” noted Long.

“Through collaborations with great minds in medicine and technology we remain committed to doing things better to improve patient outcomes while making it easier and more efficient for the many providers that care for those patients,” says Long.

About InfoBionic
InfoBionic’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s vision for its recently FDA approved third-generation platform MoMe® ARC platform is to remove the roadblocks hindering virtual and remote diagnosis and decision-making. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology. Visit https://InfoBionic.com/.

About MoMe® ARC
The company’s flagship product, the MoMe® ARC 4-in1 monitor, its 3rd Generation remote ECG monitoring device paired with their inaugural Bluetooth diagnostic 6-lead sensor is designed to aid physicians in their diagnosis of cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring. Now delivering both the convenience of a patch-type sensor and quality of a wire-based system, InfoBionic continues to be a leader the industry and has been recognized as the gold standard in remote ECG quality with its unique capability to offer true full disclosure, heartbeat-to-heartbeat data over the Cloud, allowing doctors 24/7 near real-time access to hospital telemetry-level data, and rapid diagnosis. MoMe® ARC is not intended for use as an emergency medical response system.

Media Contact

Karla Jo Helms, JOTO PR™, 727-777-4619, [email protected], jotopr.com

SOURCE InfoBionic

Molecular Devices Introduces CellXpress.ai Automated Cell Culture System, a 3D Biology Innovation Hub for Fast, Reliable Drug Discoveries


Key features of the CellXpress.ai cell culture system include:

  • Reduce Labor Costs: Until now, large-scale cell culture has demanded round-the-clock oversight. The CellXpress.ai cell culture system uses automation and AI to maintain this 24/7 schedule, improving workflows and making assays more reliable and reproducible.
  • Integrated AI-Powered Software: The hub contains next-generation technology that reliably manages the entire cell journey. Integrated machine learning-enabled software facilitates the navigation and monitoring of complex cell culture workflows, including built-in protocols for generating 2D and 3D models.
  • Efficient Protocol Development: Flexible decision-making, initiated by the operator or via machine learning-powered algorithms, allows for efficient, customizable protocol development for seamless, quality-controlled collaboration within research teams.
  • Reproducible Results: Fully automated workflows deliver reproducible results across multiple team sites, instilling confidence in experimental outcomes, enabling faster decision-making, achieving milestones more rapidly.
  • Complete Event Log and Digital Microscopy Records: A comprehensive event log confirms on-time feedings and critical task execution, supplemented by detailed digital microscopy records.

Early CellXpress.ai users include life science leader HeartBeat.bio.

“At HeartBeat.bio, we are thrilled to be one of the first external users of the CellXpress.ai Automated Cell Culture System,” said Michael Krebs, CEO of HeartBeat.bio. “Last year, we unveiled our partnership with Molecular Devices to create the world’s first fully integrated, high-throughput human cardiac organoid screening solution. With today’s official launch of the CellXpress.ai system, we have taken a significant step toward automating HeartBeat.bio’s proprietary Cardioid technology on this revolutionary platform, making highly-standardized organoids applicable for cardiac drug discovery and cardiotoxicity testing.”

To learn more or to join a community of researchers at the forefront of innovation using the CellXpress.ai cell culture system, visit CellXpressAI.com. Molecular Devices will also showcase the solution at the Society for Biomolecular Imaging and Informatics Conference 2023 in Boston, MA, during a dynamic lunch-and-learn session on Tuesday, Oct. 31, from 1:00-1:45 p.m.

About Molecular Devices, LLC.

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.

Molecular Devices is proud to be a part of Danaher, a global science and technology leader. Danaher is a global science and technology leader. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. For more information, please visit www.danaher.com.

Media Contact

Amy Smith, Molecular Devices, 1 4083344699, [email protected], Molecular Devices

SOURCE Molecular Devices

Ideal Option Among First Addiction Treatment Networks to Test for Xylazine Amidst Street Drug Epidemic


Thanks to specialized protocols and in-house laboratory services, the highly addictive animal tranquilizer can now be detected in a standard drug testing panel.

KENNEWICK, Wash., Oct. 16, 2023 /PRNewswire-PRWeb/ — Laboratory experts at Ideal Option, a national leader in evidence-based treatment for addiction to fentanyl, methamphetamine, alcohol and polysubstance, recently developed a method to definitively test for xylazine, a highly addictive animal tranquilizer.

Also known on the street as “tranq” and “the zombie drug,” xylazine has infiltrated the fentanyl supply, making the deadliest drug in the nation even deadlier. A xylazine overdose can’t be reversed with Narcan (naloxone), the life-saving nasal spray that counteracts the effects of opioids.

Developed for veterinary procedures, xylazine is used for anesthesia and pain relief in large animals, such as horses, cattle and sheep. The drug was never approved by the Federal Drug Administration (FDA) for use in humans because early trials found it caused severe sedation and depression of the central nervous system. In the early 2000s, xylazine began creeping into the illegal drug supply and, during the pandemic, became more prevalent as a cheap way to extend the high from fentanyl.

“Most treatment centers are unable to test for xylazine, so they don’t know whether patients have it in their system,” said Brian Dawson, M.D., chief medical officer of Ideal Option. In fact, xylazine is typically detected only after an overdose death, when a toxicology test is conducted, or when the U.S. Drug Enforcement Agency (DEA) analyzes confiscated samples.

However, even with limited testing data, the DEA has found xylazine in nearly every state and in about 25% of fentanyl powder samples, though rates vary from state to state.

In response to an urgent need to develop treatment protocols, in-house laboratory experts at Ideal Option have developed a testing method using analytical grade xylazine to detect the compound and add it to their existing comprehensive drug panel.

“Our lab specializes in opioid use disorder treatment, so we see a lot more exotic drugs than most labs,” said Dave Newcombe, technical laboratory director at Ideal Option. “Testing for drugs like xylazine in our standard urine panel is extremely important as it allows our addiction medicine specialists to implement the most advanced treatment protocols and provide the highest standard of patient care.”

Although guidelines for treating long-term xylazine dependence don’t exist due to the lack of studies on its pharmacology in humans, with medical guidance, recovery is possible. The first step is to identify which substances are in the patient’s system.

“For those with dependence, it is important to come to a place like Ideal Option, which has the ability to test for xylazine and uses the most up-to-date treatment options for all substances of addiction,” said Dr. Dawson.

Ideal Option has helped more than 70,000 patients through a network of over 90 outpatient clinics across 11 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oregon and Washington.

With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for multiple substances within 1-3 business days.

Patients can make an appointment by calling 1.877.522.1275 or visiting www.idealoption.com.

About Ideal Option‥

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped‥over 70,000 patients through a network of 90+ office-based‥medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are‥also‥available.‥

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.‥

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.‥

Media Contact

Olivia Roe, Ideal Option, 1 9199466644, [email protected], www.idealoption.com

Twitter, Facebook, LinkedIn

SOURCE Ideal Option



EMSAR is pleased to announce the acquisition of Omnicor Biomedical Services


The acquisition will continue the service mission for both organizations. “EMSAR’s deep healthcare OEM relationships and field service infrastructure, along with Omnicor’s on-the-ground acumen and experience, will allow the combined organization to better serve clients and their customers throughout the northeast,” said Omnicor Services President, Jim Bogett.

“The mission of both companies is to remain the trusted service provider for our valued clients, allowing them to carry out their healthcare missions. The partnership is an exciting opportunity that positions us to provide expanded service to our customers throughout the US,” said EMSAR Chief Commercial Officer, Mark Hermes.

The acquisition will further strengthen EMSAR’s service business through expansion of their equipment management, service and repair throughout the state of New York. Current EMSAR and Omnicor Biomedical customers should expect the seamless continuation of industry-leading services, with additional capabilities, service offerings and geographic coverage to follow.

“We are excited about continuing our growth story at EMSAR, focused on serving healthcare providers through both organic and M&A opportunities. The Omnicor acquisition is a great step in achieving those goals and expanding our national presence further in the Northeastern United States,” said Gauge Capital Partner, David Friedman.

About EMSAR

At our core, EMSAR is a family-oriented company that cares about our employees and our valued clients. No matter how large we get, community, relationships, and unparalleled professionalism will be our top priority. At EMSAR, we passionately strive for perfection in customized service solutions. We specialize in equipment installation, maintenance, and repair across a wide range of industries. EMSAR brings years of equipment experience and knowledge to the service of our clients and OEM partners. It is the mission of EMSAR and all our Field Technicians to be best in class for all services provided. We worry about your equipment and take care of it, so your company can focus on your core mission.

About Omnicor Biomedical

Omnicor’s factory trained, employee technicians perform required annual safety inspections, preventative maintenance, calibrations and repairs onsite to ensure equipment performance and maximize its useful life. We provide equipment, supplies, and repairs providing the medical community with reliability and exceptional customer service. As a member of the National Fire Protection Agency (NFPA), Advancement of Medical Instrumentation (AAMI), and ECRI; our staff is trained to the highest standards with over 10+ years of experience. We’ve built a brand that’s dedicated to optimizing clinical outcomes while relentlessly improving economic outcomes for our customers.

Media Contact

Megan Allen, EMSAR, 1 512-825-3383, Megan.Allen@emsar.com

SOURCE EMSAR

Lacrosse Unlimited Partners Up With Local Long Island Business to Raise Money for Pearl Heinlein Memorial Scholarship


On October 11 2023, The Pizzeria hosted a communal gathering in their Bay Shore location to celebrate Pearl’s life, selling LU apparel and pizza where proceeds from the purchases go directly to Team Pearl Girl.

“We are fortunate to have incredibly generous friends at Lacrosse Unlimited and our 2nd annual Pizza for a Good Cause event was an amazing show of support for Team Pearl Girl. Watching local communities come together for great causes is the best part of this journey,” said Cliff Weinstein, Co-founder of The Pizzeria Group.

Collectively, Lacrosse Unlimited and The Pizzeria raised over $11,000 to assist in keeping Pearl’s impact on the community ongoing.

If you are interested in purchasing apparel from the limited edition line, please visit www.pizzaforagoodcause.com

Media Contact

Marina Skelly, Lacrosse Unlimited, 1 (877)-800-5850, [email protected]

SOURCE Lacrosse Unlimited

Dedicated Medical Cannabis Clinic Opens in Hattiesburg, MS


TruReleaf MD brings to Mississippi a wealth of experience garnered over seven years of compassionate care in Florida under the name MMTCFL. As Medical Marijuana Treatment Clinics of Florida, they swiftly emerged as a cornerstone in the medical marijuana industry once medical cannabis was legalized for qualifying conditions. Their presence redefined the experience of being a medical marijuana patient, offering a natural relief option for those seeking care.

With this extensive background, TruReleaf MD aspires to rekindle the quality of life for patients through alternative treatments centered around cannabis. They firmly hold the belief that achieving relief is fundamental to regaining control over one’s life, and they are committed to equipping patients with the tools they need to make the best decisions for their own well-being.

Dr. Candace Thompson, a licensed Mississippi medical marijuana doctor, underscores the significance of this emerging industry, which promises natural alternatives to potent narcotics, ultimately aiming to curb the senseless loss of lives within the community. The clinic’s establishment provides patients with more opportunities to manage their conditions actively, propelling them closer to the life they aspire to lead.

Currently, the clinic offers in-person appointments for individuals with qualifying conditions. To schedule an appointment, patients can either visit www.getmymississippicard.com for online booking or contact 601-768-7944 to connect with a Patient Care Coordinator and schedule over the phone.

TruReleaf MD’s overarching mission is to promote public awareness and education regarding the safe access and responsible use of medical marijuana in Mississippi. Committed to adhering to state guidelines, they aim to streamline the process of obtaining a medical marijuana card, empowering patients to take charge of their healthcare journey.

Media Contact

Turner Davis, TruReleaf MD, 1 8134156465, [email protected], https://getmymississippicard.com/

SOURCE TruReleaf MD

EngagedMD Acquires MD Consents, Expanding Its Footprint in the Fertility Sector


EngagedMD, a leading platform for automating patient education and administration, announced today the acquisition of UK-based MD Consents, the parent company of Fertility Consent. This acquisition expands EngagedMD’s global footprint and brings together shared expertise and resources to deliver an enhanced offering to the fertility sector. All members of the dedicated Fertility Consent team will join the combined company ensuring exceptional service and a continued local presence in the UK market.

WASHINGTON, Oct. 16, 2023 /PRNewswire-PRWeb/ — EngagedMD, a leading platform for automating patient education and administration, announced today the acquisition of UK-based MD Consents, the parent company of Fertility Consent. This acquisition expands EngagedMD’s global footprint and brings together shared expertise and resources to deliver an enhanced offering to the fertility sector. All members of the dedicated Fertility Consent team will join the combined company ensuring exceptional service and a continued local presence in the UK market.

By acquiring MD Consents, EngagedMD is set to broaden its reach in the UK and bolster its commitment to supporting patients and clinics through the fertility journey with robust, user-friendly technology. The synergies between the two companies will combine knowledge and technology to improve patient understanding and engagement, which is crucial for the emotionally and medically complex fertility treatment process.

“EngagedMD and Fertility Consent share a common vision – to improve patient experiences through informed decision-making. This acquisition is a significant step forward in realizing that vision on a broader scale,” said Taylor Stein, Co-CEO of EngagedMD.

“We’re excited about the value this union brings to our customers and the advancements we’ll be able to bring to the fertility industry together,” added Jeff Issner, EngagedMD’s Co-CEO.

Fertility Consent is the leader in the UK market with its innovative solutions that simplify complex medical information and the consent process for patients and clinics alike. The combination of the two companies is a strong strategic fit, offering more comprehensive solutions to fertility clinics worldwide.

As EngagedMD and Fertility Consent align their operations, existing customers can look forward to an expanded range of services, better resources, and enhanced customer support.

“The combination of the EngagedMD and Fertility Consent platforms ensures our customers will continue to benefit from a robust consenting platform. We look forward to continuing to be responsive to our customers’ challenges and delivering more innovative features and services,” added Susan Diamond, Director at MD Consents.

The transaction was financed by MonCap, a Colorado-based investment firm actively focused on expanding access to care in the fertility space.

Field Fisher LLP and Polsinelli PC served as advisors to EngagedMD on this transaction.

KBS Corporate, the UK’s leading business sales specialist, advised MD Consents throughout the duration of the transaction.

For more information about EngagedMD, visit www.engagedmd.com.

About EngagedMD

People perform best when they are empowered to do the work they love. The thing doctors and nurses love is taking care of people. EngagedMD automates patient education and admin, two time-intensive functions that get in the way of carers actually caring for people. Medical practices that use EngagedMD save up to 56 minutes of patient time per day. Which means more time for high-quality consults, more space to support patients, and more moments to breathe. The effect? Happier staff taking better care of more people.

About MD Consents

MD Consents is a UK-based company that specializes in providing online consents specifically for fertility clinics. The company recently received the ‘Best e-Consent Solutions Provider, UK in the GHP Global Excellence Awards 2023. The Fertility Consent platform provides patients with consistent and engaging information about their individual treatment, which they can review in the comfort and safety of their own home before electronically completing and signing their consent forms. Fertility Consent reduces the time and resources spent by clinics on the consent process and provides documented evidence of the informed consent process.

Media Contact

Jeff Issner, EngagedMD, 1 202-524-0640, [email protected], engagedmd.com

SOURCE EngagedMD

EngagedMD Acquires MD Consents, Expanding Its Footprint in the Fertility Sector


EngagedMD, a leading platform for automating patient education and administration, announced today the acquisition of UK-based MD Consents, the parent company of Fertility Consent. This acquisition expands EngagedMD’s global footprint and brings together shared expertise and resources to deliver an enhanced offering to the fertility sector. All members of the dedicated Fertility Consent team will join the combined company ensuring exceptional service and a continued local presence in the UK market.

WASHINGTON, Oct. 16, 2023 /PRNewswire-PRWeb/ — EngagedMD, a leading platform for automating patient education and administration, announced today the acquisition of UK-based MD Consents, the parent company of Fertility Consent. This acquisition expands EngagedMD’s global footprint and brings together shared expertise and resources to deliver an enhanced offering to the fertility sector. All members of the dedicated Fertility Consent team will join the combined company ensuring exceptional service and a continued local presence in the UK market.

By acquiring MD Consents, EngagedMD is set to broaden its reach in the UK and bolster its commitment to supporting patients and clinics through the fertility journey with robust, user-friendly technology. The synergies between the two companies will combine knowledge and technology to improve patient understanding and engagement, which is crucial for the emotionally and medically complex fertility treatment process.

“EngagedMD and Fertility Consent share a common vision – to improve patient experiences through informed decision-making. This acquisition is a significant step forward in realizing that vision on a broader scale,” said Taylor Stein, Co-CEO of EngagedMD.

“We’re excited about the value this union brings to our customers and the advancements we’ll be able to bring to the fertility industry together,” added Jeff Issner, EngagedMD’s Co-CEO.

Fertility Consent is the leader in the UK market with its innovative solutions that simplify complex medical information and the consent process for patients and clinics alike. The combination of the two companies is a strong strategic fit, offering more comprehensive solutions to fertility clinics worldwide.

As EngagedMD and Fertility Consent align their operations, existing customers can look forward to an expanded range of services, better resources, and enhanced customer support.

“The combination of the EngagedMD and Fertility Consent platforms ensures our customers will continue to benefit from a robust consenting platform. We look forward to continuing to be responsive to our customers’ challenges and delivering more innovative features and services,” added Susan Diamond, Director at MD Consents.

The transaction was financed by MonCap, a Colorado-based investment firm actively focused on expanding access to care in the fertility space.

Field Fisher LLP and Polsinelli PC served as advisors to EngagedMD on this transaction.

KBS Corporate, the UK’s leading business sales specialist, advised MD Consents throughout the duration of the transaction.

For more information about EngagedMD, visit www.engagedmd.com.

About EngagedMD

People perform best when they are empowered to do the work they love. The thing doctors and nurses love is taking care of people. EngagedMD automates patient education and admin, two time-intensive functions that get in the way of carers actually caring for people. Medical practices that use EngagedMD save up to 56 minutes of patient time per day. Which means more time for high-quality consults, more space to support patients, and more moments to breathe. The effect? Happier staff taking better care of more people.

About MD Consents

MD Consents is a UK-based company that specializes in providing online consents specifically for fertility clinics. The company recently received the ‘Best e-Consent Solutions Provider, UK in the GHP Global Excellence Awards 2023. The Fertility Consent platform provides patients with consistent and engaging information about their individual treatment, which they can review in the comfort and safety of their own home before electronically completing and signing their consent forms. Fertility Consent reduces the time and resources spent by clinics on the consent process and provides documented evidence of the informed consent process.

Media Contact

Jeff Issner, EngagedMD, 1 202-524-0640, [email protected], engagedmd.com

SOURCE EngagedMD

MultiTech and DeltaM2M c collaborate to increase sales of LoRa solutions in the Nordic Region


From MultiTech, DeltaM2M in the Nordic Region will now have access to the world’s most comprehensive LoRaWAN-based sensor-to-cloud portfolio of products.

MOUNDS VIEW, Minn., Oct. 16, 2023 /PRNewswire-PRWeb/ — Multi-Tech Systems Inc. a leading global supplier of Internet of Things (IoT) devices and services, has signed a distributor agreement with DeltaM2M to increase market share in the Nordic Region.

MultiTech recently announced the extension of its MultiTech Radio Bridge line of wireless sensors with LoRa® technology to communicate over European unlicensed radio spectrum. The sensors utilize the LoRaWAN® wireless standard and are engineered for long range, low cost, and extended battery life applications.

With the introduction of the sensor line in Europe, MultiTech is now able to offer our partners and customers the opportunity to seamlessly deploy their IoT applications in Europe and North America with best-in-class system performance.

“Solution providers, system integrators, and OEMs now have a simplified path to develop and deploy new connected solutions,” said Stefan Lindvall, CEO of MultiTech. “We are very proud to offer the world’s most comprehensive LoRaWAN-based sensor-to-cloud portfolio of products and tools and look forward to continuing our commitment to help businesses leverage the true power of IoT within their industries.”

The wide range of IoT products from MultiTech include LoRaWAN sensors, LoRaWAN gateways, cellular industrial gateways, cellular routers, cellular modems and cloud software tools and services for configuration, device, application, and cybersecurity management.

“DeltaM2M is a company, I have known for many year s “, said François Casteleyn , Sales Director EMEA Central, MultiTech. “I t is a comp any known for working very closely with their customers regarding new projects”.

“MultiTech is an early leader in the private LoRa area and an obvious choice to enable enhanced connectivity for our customers,” said Torben Deleuran, CEO of DeltaM2M. “This have given us an opportunity to improve service to our customers.”

About DeltaM2M DeltaM2M have been helping customers since 2007 and is a M2M and IoT-specialist in the Nordic Region. The company is located in Fredensborg, Denmark. For more information visit https://deltaM2M.dk or follow DeltaM2M on LinkedIn.

Pull Quote

From MultiTech, DeltaM2M in the Nordic Region will now have access to the world’s most comprehensive LoRaWAN-based sensor-to-cloud portfolio of products.

Media Contact

Matthew MacDowell, MultiTech, +1 763-717-5528, [email protected], https:.//www.MultiTech.com

Torben Deleuran, DeltaM2M, +45 4848 0148, [email protected], https://deltaM2M.dk

Twitter

SOURCE MultiTech